FutuRx Biotech Accelerator

FutuRx is unusual in the Israeli biotech ecosystem because its founding cap table reads like a strategic alliance rather than a venture fund. Established in 2014 in Ness Ziona, the accelerator was created jointly by OrbiMed Israel Partners, Johnson and Johnson Innovation through JJDC, and Takeda Ventures, with Leaps by Bayer joining as an investor in 2020. The structure means that every company entering the FutuRx portfolio begins life with simultaneous exposure to four global pharmaceutical and healthcare investors, which materially changes the early development trajectory in ways that pure-play seed funds cannot replicate. The accelerator has now established more than 20 companies and has positioned itself as the primary mechanism for translating Israeli academic biotechnology into clinically credible therapeutic assets.

The operating thesis is narrow and intentional. FutuRx invests in highly novel, early-stage drug discovery projects where the underlying biology is differentiated and the likely path is preclinical development through proof of concept. The firm explicitly does not pursue digital health, medical devices or AI-only platforms; it is a therapeutics accelerator with a preference for first-in-class biology. The strategic investor model means companies are typically built around technologies licensed from Israeli research institutes, with FutuRx providing the formation capital, infrastructure and early development plan, and the corporate investors providing both capital and downstream optionality. The thesis is that an Israeli academic founder paired with global pharma diligence early in formation produces better drug candidates than the same founder running a conventional seed-funded biotech.

The portfolio reflects this discipline. Bsense Bio Therapeutics, RNAble Therapeutics, Skip Therapeutics, CatchMe Therapeutics and Circuit-Bio are among the companies the accelerator has formed and disclosed publicly, spanning RNA therapeutics, neurology, oncology and novel modality biology. The firm reports having established roughly 20 companies across its operating history, with the typical trajectory running from formation through preclinical proof of concept to a Series A led by external investors, often with one or more of the founding strategic investors continuing to participate. For scientific founders the relevant signal is that FutuRx-formed companies have a credible track record of attracting tier-one Series A capital, and the strategic investors at formation create natural partnership pathways that pure seed-funded biotechs typically have to construct on their own years later.

On stage and check size, FutuRx operates at pre-seed and seed with initial commitments in the USD 1 million to USD 5 million range. The funding model includes infrastructure access, lab space, regulatory and clinical development support, and a structured operating plan, in exchange for meaningful equity at formation. Founders should treat the engagement as company creation rather than minority investment; the accelerator typically takes a substantial equity position in exchange for the bundled support, and the implicit deal is that the first 12 to 24 months of company building will run inside the FutuRx framework with strategic investor input on development priorities. Companies that successfully reach proof of concept then raise external Series A rounds at materially better terms than they could have absent the accelerator’s involvement.

Decision-making routes through the accelerator’s investment committee, which includes representatives from OrbiMed Israel Partners, JJDC, Takeda Ventures and Leaps by Bayer. The structure means that consensus across multiple strategic investors is required for company formation, which is both a strength and a constraint: it filters for genuinely differentiated biology, but it also means the diligence process is more involved than a single-fund seed. Day-to-day operating leadership sits with the FutuRx team based in Ness Ziona, who manage the portfolio relationship and the development plans for each company.

The right approach for scientific founders is through Israeli research institutes and tech transfer offices, all of which have established sourcing relationships with FutuRx. The accelerator publicly invites direct submissions of project proposals and runs structured intake cycles, but warm referrals from Israeli academic leaders or from existing FutuRx alumni materially improve the conversion rate. Founders should arrive with a clear scientific differentiation story, not a clinical or commercial narrative; FutuRx is a discovery investor and will diligence accordingly.

What founders should know is that FutuRx is the wrong partner if you are building digital health, medical devices or AI tooling, and the right partner if you have novel therapeutic biology that benefits from being run through a multi-pharma operating framework from day one. The equity expectations are substantial, the diligence is rigorous, and the strategic investor structure creates both opportunity and constraint. For first-in-class biology coming out of Israeli academia, few formation paths in global biotech are more credible.